XELODA IN THE TREATMENT OF METASTATIC COLORECTAL CANCER


Cite item

Full Text

Abstract

The article is dedicated to the modern potentials and prospects of use of Xeloda (capecitabine) in the treatment of metastatic colorectal cancer (mCRC). Clinical studies have demonstrated clinical efficacy of Xeloda in the 1st and 2nd lines of treatment of mCRC as monotherapy and in combination with oxaliplatin and irinotecan. Randomized multicenter studies have shown equal efficacy of combined treatment regimens including Xeloda and regimens including the daily infusion of 5-fluorouracil. Inclusion of Xeloda in the treatment regimens with targeted drugs (bevacizumab and cetuximab) was highly effective and safe. Administration of Xeloda does not require venous access and, therefore, allows the out-patient treatment.

References

  1. Thirion P, Michiels S, Pignon JP, et al., Meta-Analysis Group in Cancer. Modulation of fluorouracilby leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
  2. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44.
  3. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
  4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
  5. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
  6. Aprile G, Mazzer V, Morozo S, et al. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anti-Cancer Drugs 2009;20:217-29.
  7. Van Cutsem E, Hoff P, Harper P, et al. Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-97.
  8. Hoff PM, Cassidy J, Schmoll HJ. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist 2001;6(Suppl. 4):3-11.
  9. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-FU plus LV in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001;37:597-604.
  10. Э.Чу, М. Магацан, А. Элфики и др. Противоопухолевые средства в книге. Химиотерапия злокачественных новообразований / Под. ред. Э.Чу, В.Де Вита-младший. М., 2008. C. 134-138.
  11. Vallbohmer D, Yang DY, Kuramochi H, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2008;31:413-18.
  12. Porschen R, Arkenau HT, Kubicka S, et al. Capecitabine plus oxaliplatin versus 5-fluorouracil/leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer. J Clin Oncol 2007;25:4217-23.
  13. Bennouna J, Ducreux M, Hebbar M, et al. Preliminary efficacy findings from a randomized phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV +oxaliplatin (FOLFOX-6) as first line treatment for metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007;220:272.
  14. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12.
  15. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523-29.
  16. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; [Accessed 2008].
  17. Arkenau H-T, Arnold D, Cassidy J, еt al. Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. J Clin Oncol 2008;26:5910-17.
  18. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Meeting Abstracts 2007;25:4030.
  19. Eduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España et al.Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30.
  20. Rainer Porschen, Hendrik-Tobias Arkenau, Stephan Kubicka et al. Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-23.
  21. Rothenberg ML, Navarro M, Butts C, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Meeting Abstracts 2007;25:4031.
  22. Sukumaran S, Pavlakis N, Pittman KB, et al. Price Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2009;27(Suppl.):e15100.
  23. Meropol NJ, Gold PJ, Diasio RB, et al. Lund, Edith Mitchell, and Roland Schwarting. Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2006;24:4069-77.
  24. Manzano JL, Diaz N, Rolfo C, et al. Phase II study of capecitabine combined with oxaliplatin (XELOX) and CPT-11 (XELIRI) for advanced colorectal cancer patients previosly treated with 5-FU-based chemotherapy. Meeting Proceedings 43rd ASCO 2007. abstr. 14544.
  25. Rao S, Cunningam D, Price T, et al. Phase II study of capecitabine and mitomicin C as first-line treatment with advanced colorectal cancer. Br J Cancer 2004:1-5.
  26. Schmiegel WH, Reinacher-Schick A, Freier W, G. Dietrich, D. Arnold et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. ASCO Meeting Abstracts 2007;25:4034.
  27. Beslija S, Banjin M, Jungic S, et al. Updated phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC). ASCO Meeting Abstracts 2009;27:15064.
  28. Hochster HS, Harr LL, Ramanathan RK, et al. Safety and efficasy of oxaliplatin/ fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mRCC). Final analysis of the TREE-Study. J Clin Oncol 2006;24(148s Suppl.):abstr. 3510.
  29. Ducreux M, Adenis A, Mendiboure J, et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). ASCO Meeting Abstracts, May 2009; 27: 4086.
  30. Tebbutt NC, Gebski V, Wilson K, et al. International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. ASCO Meeting Abstracts 2009;27:4023.
  31. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2010;28:3540.
  32. Kretzschmar A, Behringer DM, Wolff T, et al. Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial. ASCO Meeting Abstracts 2010;28:355.
  33. Toll J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19(4):734-38.
  34. Lee W, Lockhart C, Kim RB, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005;10:104-11.
  35. Ezzledin H, Diasio R. DPD deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181-89.
  36. Saif MW, Diasio R. Is capecitabine safe in GI cancer patients with dihydropyrimidine dehydrogenase (DPD) deficiency? Clin Colorectal Cancer 2006;5:359-62
  37. Wildiers H. Chemotherapy dosing in elderly cancer patients - SIOG guidelines. Eur J Cancer 2007;5(5 Suppl.):406-08.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies